GLP-1 and incretin compared
Retatrutide vs semaglutide
An investigational triple agonist and an approved GLP-1 agonist, side by side.
Retatrutide is an investigational agonist of the GIP, GLP-1 and glucagon receptors, and semaglutide acts on the GLP-1 receptor.1,2,3 An early report gives retatrutide's half-life as approximately 6 days, and the Ozempic label gives semaglutide's as approximately 1 week.4,3
Semaglutide has been approved in the US since 2017, while the FDA says retatrutide is not a component of an FDA-approved drug.3,5 The weight figures below come from separate trials. A 2026 review, with evidence to 11 September 2026, reports no completed head-to-head trial of retatrutide and names TRANSCEND-T2D-2, against semaglutide in type 2 diabetes, as a randomised comparison that could support one.6,7
| Fact | Retatrutide | Semaglutide |
|---|---|---|
| What it is | An investigational agonist of the GIP, GLP-1 and glucagon receptors1,2 | A GLP-1 receptor agonist marketed by Novo Nordisk3 |
| How it comes | Once-weekly subcutaneous injection in trials; not a component of an FDA-approved drug6,5 | Ozempic pens of 0.68, 1.34 or 2.68 mg/mL, injected under the skin once weekly3 |
| Half-life | ||
| Doses and results | ||
| Status | Not a component of an FDA-approved drug, and not approved by the TGA or a comparable international regulator5,9 | First approved in the US in 2017, as Ozempic; also approved as Wegovy3,11 |
Last reviewed . Sources are listed below.
How they differ
Retatrutide adds the GIP and glucagon receptors to the GLP-1 receptor that semaglutide acts on, and in obese mice the authors report that weight loss was augmented by glucagon receptor-mediated increases in energy expenditure.8 A 2026 review states that improvement in blood sugar control supports the net efficacy of the combined molecule rather than a separately quantified benefit for each receptor.2
The weight figures in the table come from different trials: retatrutide's ran 80 weeks and was funded by Eli Lilly, and semaglutide's ran 68 weeks and was funded by Novo Nordisk.6,7
Logged in Milligram
- Retatrutide: 49% of people who logged a dose in Milligram logged it in the 90 days to 15 November 2026.
- Semaglutide: Too few people logged it to show a share.
Shares of people who logged a dose in Milligram in the 90 days to 15 November 2026, shown only where at least 50 people logged three or more doses of the compound.
What is not known
A 2026 review states that retatrutide's indications, contraindications and prescribing instructions require regulatory review, and that rare events, pregnancy exposure and long-term effects need larger datasets and dedicated follow-up.2 The TGA states that any retatrutide product accessed outside of clinical trials could be a counterfeit product.9
In a boxed warning, the Ozempic label states that semaglutide causes thyroid C-cell tumors in rodents, that it is unknown whether Ozempic does in humans, and that Ozempic is contraindicated with a personal or family history of medullary thyroid carcinoma or with MEN 2.3
References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. Peer-reviewed paper (phase 2), 2023. PMID 37366315
- Mateescu DM, et al. Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence. Peer-reviewed narrative review, full text (evidence to 11 September 2026), 2026. PMC13708278
- Novo Nordisk Pharmaceutical Industries, LP. OZEMPIC (semaglutide) injection, for subcutaneous use. Prescribing information, Novo Nordisk. US label (DailyMed), 2026. DailyMed label
- Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Peer-reviewed paper (phase 1b), 2022. PMID 36354040
- US Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Regulator web page, 2026. fda.gov
- Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. Peer-reviewed paper (phase 3), 2026. PMID 42814954
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. Journal article (PubMed), 2021. PMID 33567185
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Peer-reviewed paper (preclinical and phase 1), 2022. PMID 35985340
- Therapeutic Goods Administration (Australia). TGA tests counterfeit retatrutide product following serious adverse event report. Regulator web page, 2026. tga.gov.au
- European Medicines Agency. Ozempic: summary of product characteristics (EPAR product information). EU product information, 2026. ema.europa.eu
- Novo Nordisk Pharmaceutical Industries, LP. WEGOVY (semaglutide) injection and tablets. Prescribing information, Novo Nordisk. US label (DailyMed), 2026. DailyMed label